Clinical experience with the use of infliximab in 44 patients with Crohn's disease;Experiência clínica com o uso de infliximab em 44 portadores de doença de Crohn

Arquivos de Gastroenterologia

Volumn 40, Issue 3, 2003, Pages 198-200

  Steinwurz, Flavio ^a  

^a HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

Author keywords

Antibodies, monoclonal; Crohn disease, drug therapy; Gastrointestinal agents

Indexed keywords

CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MESALAZINE;

ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CROHN DISEASE; DRUG EFFICACY; FEMALE; HUMAN; IMMUNOTHERAPY; MALE; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0842334484     PISSN: 00042803     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0004-28032003000300012     Document Type: Article

References (20)

1. Arnott ID, McDonald D, Williams A, Ghosh S. Clinical use of infliximab in Crohn's disease: the Edinburgh experience. Aliment Pharmacol Ther 2001;15:1639-46.
2. Asakura H, Yao T, Matsui T, Koganei K, Fukushima T, Takazoe M, Hobara R, Nakano H, Okamura S, Matsueda K, Kashida H, Makyiama K, Hiwatashi N, Kashiwagi K, Hibi T. Efficacy of treatment with chimeric monoclonal antibody (infliximab) to tumor necrosis factor-alpha for Crohn's disease in Japan: evaluation by rapid turnover proteins, and radiologic and endoscopic findings. J Gastroenterol Hepatol 2001;16:763-9.
3. Farrell RJ, Shah AS, Lodhavia PJ, Alsahli M, Falchuk KR, Michetti P, Peppercorn MA. Clinical experience with infliximab therapy in 100 patients with Crohn's disease. Am J Gastroenterol 2000;95:3490-7.
4. Feagan BG, Enns R, Fedorak RN, Panaccione R, Paré P, Steinhart AH, Wild G. Infliximab for the treatment of Crohn's disease: efficacy, safety and pharmacoeconomics. Can J Clin Pharmacol 2001;8:188-98.
5. Garnett WR, Yunker N. Treament of Crohn's disease with infliximab. Am J Health Syst Pharm 2001;58:307-16.
6. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S. Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P. Maitenance infliximab for Crohn's disease: the accent I randomised trial. Lancet 2002;359:1541-9.
7. Hommes DW, van der Heisteeg BH, van der Spek M, Barteisman JF, van Deventer SJ. Infliximab treatment for Crohn's disease: one year experience in a Dutch academic hospital. Inflamm Bowel Dis 2002;8:81-6.
8. Keating GM, Perry CM. Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis. Biodrugs 2002;16:111-48.
9. Mortimore M, Gibson PR, Selby WS, Radford-Smith GL, Florin TH. Early Australian experience with infliximab, a chimeric antibody against tumor necrosis factor-alpha, in the treatment of Crohn's disease: is its efficacy augmented by steroids-sparing immunosuppressive therapy? The Infliximab User Group. Intern Med J 2001;31:146-50.
10. Panaccione R. Infliximab for the treatment of Crohn's disease: review and indications for clinical use in Canada. Can J Gastroenterol 2001;15:371-5.
11. Paré P. Management of fistulas in patients with Crohn's disease: antibiotic to antibody. Can J Gastroenterol 2001;15:751-6.
12. Present DH. The efficacy of infliximab in Crohn's disease-healing of fistulae [review article]. Aliment Pharmacol Ther 1999;13 Suppl 4:23-8.
13. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podilsky DK, Sands BE, Breakman T, Dewoody KL, Schaible TF, van Deventer SJ. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-405.
14. Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Sandborn WJ. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterol 2001;96:722-9.
15. Rutgeerts P. A critical assesment of new therapies in inflammatory bowel disease. J Gastroenterol Hepatol 2002;17 suppl:S176-S85.
16. Sample C, Bailey RJ, Todoruk D, Sadowski D, Gramlich L, Milan M, Cherry R, Ma M, Lalor E, McKaigney J, Sherbaniuk R, Matic K, Switzer C, Fedorak RN. Clinical experience with infliximab for Crohn's disease: the first 100 patients in Edmonton, Alberta. Can J Gastroenterol 2002;16:165-70.
17. Sandborn WJ. Transcending conventional therapies: the role of biologic and other novel therapies. Inflamm Bowel Dis 2001;7 Suppl 1:S9-S16.
18. Steinwurz F. Estudo evolutivo de fistulas na doença de Crohn. Arq Gastroenterol 1999;36:207-9.
19. Steinwurz F. Conceitos atuais no tratamento clínico da doença de Crohn. Avanços Médicos 2000;6:106-7.
20. Vermeire S, Louis E, Carbonez A, Van Assche G, Norman M, Belaiche J, De Vos M, Van Gossum A, Pescatore P, Flasse R, Pelckmans P, Reynaert H, D'Haens G, Rutgeerts P. Demographic and clinical parameters influencing the short-term outcome of anti tumor necrosis factor (infliximab) treatment in Crohn's disease. Am J Gastroenterol 2002;97:2357-63.